FINWIRES · TerminalLIVE
FINWIRES

Bank of England Leaves Key Rate Unchanged but Soaring Energy Prices Signal Policy Rethink

作者

-- The Bank of England held its key rate steady at 3.75% and reiterated its readiness to act as the ongoing war in the Middle East pushes up energy costs and creates upside risks for inflation.

The UK central bank's Monetary Policy Committee voted 8-1 in favor of a hold, with lone dissenter Chief Economist Huw Pill voting for a 25 basis-point increase to 4%, citing the "clear upward shift in risks" to achieving the BoE's 2% inflation target, according to a Thursday release. At its previous meeting in March, the committee voted unanimously to leave the bank rate unchanged.

Based on the latest data from the Office for National Statistics, the country's annual inflation rate climbed to 3.3% in March from the previous month's 3%, with the core rate, which excludes energy prices, edging down to 3.1% from 3.2%.

The BoE expects inflation to come in higher later in 2026 on the back of soaring energy prices, with "material" second-round effects posing a risk in price- and wage-setting. Specifically, the headline inflation rate is currently expected by BoE staff to decline to an average of 3.1% in the second quarter before picking up to 3.3% in the third quarter.

Given the high uncertainty around global energy prices and the potential impact on domestic inflation, the BoE set out three scenarios to determine how the war could affect the UK economy. In the worst-case Scenario C, the bank rate increases to 5.25% by the first quarter of 2027 on expectations that inflation would peak at 6.2% and remains largely above target.

"If the shock appears to be short-lived or the economy weaker, policy should place relatively more weight on avoiding unnecessary contraction in activity. If second-round effects are likely to be greater, policy should focus on returning inflation back to target more quickly," BoE Governor Andrew Bailey said.

The MPC said it will closely monitor the situation in the Middle East and that it stands ready to implement the necessary measures to ensure that inflation remains on course to meet the BoE's 2% target over the medium term.

相关文章

Sectors

行业动态:消费者

周四下午,消费类股票走高,道富消费必需品精选行业SPDR ETF (XLP)上涨1.4%,道富非必需消费品精选行业SPDR ETF (XLY)上涨0.4%。 公司方面,兰姆韦斯顿(LW)股价上涨1.6%,此前股东Starboard Value周四致信董事会,表示公司应召开投资者日活动,并将盈利预期调整至正常水平。

$LW
Research

研究快讯:CFRA维持对Firstenergy Corp.股票的买入评级。

独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下:我们将12个月目标股价下调1美元至55美元,市盈率为20倍,基于未来12个月每股收益预期2.75美元,高于五年平均水平15.6倍。我们将2026年每股收益预期下调0.02美元至2.72美元,并将2027年每股收益预期下调0.01美元至2.93美元。第一季度核心每股收益同比增长7.5%,打破了此前连续三个季度下滑的局面,我们预计在整个预测期内,增长势头将持续。 我们观察到数据中心需求呈现积极趋势,长期合同需求(4.3 GW)自 2026 年 2 月(4.1 GW)以来增长了 4%,自 2025 年 2 月(2.9 GW)以来增长了 47%;同时,在建项目需求(14.9 GW)自 2026 年 2 月(12.9 GW)以来增长了 15%,自 2025 年 2 月(6.1 GW)以来增长了一倍以上。自 2022 年以来,FE 已将基础运维成本降低了 2 亿美元以上(15%),预计 2026 年第一季度将同比进一步下降约 5%,同时可靠性指标也得到提升。我们认为,FE 的成本控制、服务质量的提升以及具有竞争力的价格定位,将转化为更有利的费率调整结果、更低的拒付风险以及更高的潜在净资产收益率 (ROE)。

$FE
Australia

市场动态:FDA专家组投票反对阿斯利康乳腺癌药物的益处

据彭博社周四报道,美国食品药品监督管理局(FDA)肿瘤药物咨询委员会否决了阿斯利康(AZN)用于治疗乳腺癌的候选药物卡美司群(Camizestrant)的疗效。 彭博社称,六名委员会成员投票反对该药物,原因是他们对试验设计及其在临床应用中的潜在影响存在分歧。 根据一份简报文件,该药物试验达到了无进展生存期(PFS)的主要终点以及无进展生存期2(PFS2)终点,但FDA认为PFS2不适合作为监管决策的终点。 (市场动态新闻来源于与全球市场专业人士的对话。这些信息据信来自可靠来源,但可能包含传闻和推测。准确性无法保证。)Price: $189.60, Change: $+4.40, Percent Change: +2.37%

$AZN